Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

COX-2 inhibitors reported by UPSA

Jan. 5, 1998

VX-740 advances in preclinical studies

Jan. 2, 1998

UPSA claims new COX-2 inhibitors for inflammation, pain and other disorders

Dec. 31, 1997

FDA approves Arthrotec, a new arthritis medication with NSAID efficacy and improved GI safety

Dec. 30, 1997

New antiinflammatory compounds disclosed by Glycomed

Dec. 30, 1997

Alexion files IND for C5 inhibitor treatment for rheumatoid arthritis

Dec. 29, 1997

Phase IIb trial of TCR vaccine for rheumatoid arthritis begins

Dec. 29, 1997

Procter & Gamble's COX-2 inhibitor in preclinical testing

Dec. 24, 1997

Hyal discontinues development of osteoarthritis drug

Dec. 18, 1997

Pennsaid submitted to FDA for approval

Dec. 16, 1997

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...